Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Metabolon Partners with China Kadoorie Biobank to Advance Precision Health
The landmark multiomics study will examine how lifestyle, environmental, socioeconomic, and genetic…
Psoriatic Disease To Take Center Stage at the UN General Assembly: IFPA Calls for Greater Recognition of Psoriatic Disease During UN High-Level Meetings
STOCKHOLM, Sept. 11, 2025 /PRNewswire/ -- The International Federation of Psoriasis Associations…
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to…
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
September 09, 2025 11:00 ET | Source: Chiesi Global Rare Diseases Results…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
![U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease](https://i3.wp.com/mms.businesswire.com/media/20250905840795/en/1247790/22/Takeda_Red_Logo_2021.jpg?w=420&resize=420,280&ssl=1 "U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease"){kind=logo}
U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce…
London musician with brain tumour inspires Brighton triathlon fundraiser
Tuesday 26 August, 2025 A talented musician from London, who died from…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care
RIYADH, Saudi Arabia, Aug. 24, 2025 (GLOBE NEWSWIRE) -- In a rare…